A Medicare Advantage denial from Humana triggers a five-level appeal process that is substantially stronger than the two-level path in most commercial plans. The HHS OIG has documented that MA plans improperly deny a non-trivial fraction of prior-auth requests. CMS's 2024 final rule (CMS-4201-F) tightened decision timeframes and forced MA plans to provide specific denial reasons. The appeal path is engineered for reversal — if you use it correctly.
This guide is the specific playbook for a Humana Medicare Advantage denial — the $210M DOJ False Claims Act settlement, the 2024 CMS intermediate sanctions and enrollment freeze, and Estate of Johnson v. Humana are the backdrop. What follows: the documented reasons Humana issues this category of denial, what federal and state law actually require Humana to do, the written appeal step by step, the evidence to gather, and the deadlines that control the whole process. Every statistic is sourced to KFF, CMS, HHS OIG, published court filings, or Humana's own public disclosures.